NVS Novartis AG

  1. Stocks
  2. Healthcare
  3. NYSE: NVS

Price (delayed)

$151.5

Market cap

$289.08B

P/E Ratio

21.58

Dividend/share

$4.77

EPS

$7.02

Enterprise value

$329.2B

?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: 54
Relative Profitability: Rel. Profitability: 94

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world ...

Highlights
The gross profit rose by 6% year-on-year
Novartis AG's revenue has increased by 6% YoY
The quick ratio is down by 31% since the previous quarter but it is up by 4% year-on-year
The company's EPS rose by 9% YoY but it fell by 2.6% QoQ
The company's debt has surged by 50% YoY and by 33% QoQ
The stock's P/E is 21% more than its 5-year quarterly average of 17.5 and 12% more than its last 4 quarters average of 19.0
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.novartis.com/
Peers: PFE MRK JNJ TEVA

Key stats

What are the main financial stats of NVS

NVS stock price

How has the Novartis AG stock price performed over time
Intraday
1.73%
1 week
0.38%
1 month
-0.34%
1 year
28.91%
YTD
9.89%
QTD
-0.82%

Financial performance

How have Novartis AG's revenue and profit performed over time
Revenue
$56.58B
Gross profit
$42.65B
Operating income
$17.22B
Net income
$13.53B
Gross margin
75.4%
Net margin
23.9%
NVS's operating income is up by 9% year-on-year but it is down by 2.4% since the previous quarter
The gross profit rose by 6% year-on-year
Novartis AG's revenue has increased by 6% YoY
The company's net income rose by 5% YoY but it fell by 3.2% QoQ

Price vs fundamentals

How does NVS's price correlate with its fundamentals

Growth

What is Novartis AG's growth rate over time

Valuation

What is Novartis AG stock price valuation
NVS P/E details
P/E
21.58
P/B
7.51
P/S
5.11
EV/EBIT
19.34
EV/EBITDA
11.74
EV/Sales
5.82
The stock's P/E is 21% more than its 5-year quarterly average of 17.5 and 12% more than its last 4 quarters average of 19.0
The company's EPS rose by 9% YoY but it fell by 2.6% QoQ
NVS's P/B is 64% above its 5-year quarterly average of 4.5 and 21% above its last 4 quarters average of 6.1
The company's equity fell by 17% QoQ
The P/S is 14% more than the 5-year quarterly average of 4.4 and 9% more than the last 4 quarters average of 4.6
Novartis AG's revenue has increased by 6% YoY

Efficiency

How efficient is Novartis AG business performance
The ROIC has declined by 14% year-on-year and by 13% since the previous quarter
Novartis AG's ROA has decreased by 7% from the previous quarter and by 3.9% YoY
NVS's ROE is up by 3.3% YoY but it is down by 3.1% QoQ
The company's return on sales fell by 2.6% QoQ

Dividends

What is NVS's dividend history
Dividend details
DPS
$4.77
Dividend yield
3.15%
Payout ratio
68%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Novartis AG financials performed over time
NVS's total assets is 49% greater than its total liabilities
The quick ratio is down by 31% since the previous quarter but it is up by 4% year-on-year
NVS's total liabilities is up by 29% year-on-year and by 24% since the previous quarter
The company's debt is 22% higher than its equity
The debt to equity has soared by 58% from the previous quarter and by 51% YoY
The company's debt has surged by 50% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.